{"authors": [["Fern\u00e1ndez-Due\u00f1as", "V\u00edctor", "V", "Unitat de Farmacologia, Departament Patologia i Terap\u00e8utica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain."], ["P\u00e9rez-Ar\u00e9valo", "Andrea", "A", "Unitat de Farmacologia, Departament Patologia i Terap\u00e8utica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain."], ["Altafaj", "Xavier", "X", "Unitat de Farmacologia, Departament Patologia i Terap\u00e8utica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain."], ["Ferr\u00e9", "Sergi", "S", "Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, United States."], ["Ciruela", "Francisco", "F", "Unitat de Farmacologia, Departament Patologia i Terap\u00e8utica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain."]], "date": "2017-11-22", "id": "29213228", "text": "", "doi": "10.3389/fnins.2017.00652", "title": "Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease.", "journal": ["Frontiers in neuroscience", "Front Neurosci"]}